ID   POL_FOAMV               Reviewed;        1143 AA.
AC   P14350; O12528; O12817; Q76U32; Q98835;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2006, sequence version 2.
DT   29-APR-2015, entry version 126.
DE   RecName: Full=Pro-Pol polyprotein;
DE   AltName: Full=Pr125Pol;
DE   Contains:
DE     RecName: Full=Protease/Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.1.26.4;
DE              EC=3.4.23.-;
DE     AltName: Full=p87Pro-RT-RNaseH;
DE   Contains:
DE     RecName: Full=Protease/Reverse transcriptase;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.4.23.-;
DE     AltName: Full=p65Pro-RT;
DE   Contains:
DE     RecName: Full=Ribonuclease H;
DE              Short=RNase H;
DE              EC=3.1.26.4;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
DE     AltName: Full=p42In;
GN   Name=pol;
OS   Human spumaretrovirus (SFVcpz(hu)) (Human foamy virus).
OC   Viruses; Retro-transcribing viruses; Retroviridae; Spumaretrovirinae;
OC   Spumavirus.
OX   NCBI_TaxID=11963;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA], AND SEQUENCE REVISION.
RA   Fluegel R.M.;
RL   Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Schmidt M., Herchenrder O., Heeney J.L., Rethwilm A.;
RT   "Long terminal repeat U3-length polymorphism of human foamy virus.";
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-742.
RX   PubMed=2451755;
RA   Maurer B., Bannert H., Darai G., Fluegel R.M.;
RT   "Analysis of the primary structure of the long terminal repeat and the
RT   gag and pol genes of the human spumaretrovirus.";
RL   J. Virol. 62:1590-1597(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 741-886.
RX   PubMed=2820721;
RA   Fluegel R.M., Rethwilm A., Maurer B., Darai G.;
RT   "Nucleotide sequence analysis of the env gene and its flanking regions
RT   of the human spumaretrovirus reveals two novel genes.";
RL   EMBO J. 6:2077-2084(1987).
RN   [5]
RP   ACTIVE SITE OF PROTEASE, AND MUTAGENESIS OF ASP-24 AND SER-25.
RX   PubMed=7474150;
RA   Konvalinka J., Loechelt M., Zentgraf H., Fluegel R.M.,
RA   Kraeusslich H.-G.;
RT   "Active foamy virus proteinase is essential for virus infectivity but
RT   not for formation of a Pol polyprotein.";
RL   J. Virol. 69:7264-7268(1995).
RN   [6]
RP   MUTAGENESIS OF PRO-152; PRO-169; PRO-193; ASP-599 AND TYR-672.
RX   PubMed=7544460; DOI=10.1093/nar/23.14.2621;
RA   Kogel D., Aboud M., Fluegel R.M.;
RT   "Mutational analysis of the reverse transcriptase and ribonuclease H
RT   domains of the human foamy virus.";
RL   Nucleic Acids Res. 23:2621-2625(1995).
RN   [7]
RP   CHARACTERIZATION OF POLYPROTEIN.
RX   PubMed=8551561;
RA   Loechelt M., Fluegel R.M.;
RT   "The human foamy virus pol gene is expressed as a Pro-Pol polyprotein
RT   and not as a Gag-Pol fusion protein.";
RL   J. Virol. 70:1033-1040(1996).
RN   [8]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=9696869;
RA   Pfrepper K.-I., Rackwitz H.R., Schnoelzer M., Heid H., Loechelt M.,
RA   Fluegel R.M.;
RT   "Molecular characterization of proteolytic processing of the Pol
RT   proteins of human foamy virus reveals novel features of the viral
RT   protease.";
RL   J. Virol. 72:7648-7652(1998).
RN   [9]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=Isolate HSRV2;
RX   PubMed=11086125;
RA   Imrich H., Heinkelein M., Herchenroder O., Rethwilm A.;
RT   "Primate foamy virus Pol proteins are imported into the nucleus.";
RL   J. Gen. Virol. 81:2941-2947(2000).
RN   [10]
RP   CHARACTERIZATION OF REVERSE TRANSCRIPTASE.
RX   PubMed=12829852; DOI=10.1128/JVI.77.14.8141-8146.2003;
RA   Delelis O., Saib A., Sonigo P.;
RT   "Biphasic DNA synthesis in spumaviruses.";
RL   J. Virol. 77:8141-8146(2003).
RN   [11]
RP   CHARACTERIZATION OF INTEGRASE.
RX   PubMed=14963145; DOI=10.1128/JVI.78.5.2472-2477.2004;
RA   Juretzek T., Holm T., Gartner K., Kanzler S., Lindemann D.,
RA   Herchenroder O., Picard-Maureau M., Rammling M., Heinkelein M.,
RA   Rethwilm A.;
RT   "Foamy virus integration.";
RL   J. Virol. 78:2472-2477(2004).
RN   [12]
RP   REVIEW.
RX   PubMed=12908768;
RA   Fluegel R.M., Pfrepper K.-I.;
RT   "Proteolytic processing of foamy virus Gag and Pol proteins.";
RL   Curr. Top. Microbiol. Immunol. 277:63-88(2003).
RN   [13]
RP   REVIEW.
RX   PubMed=15358259; DOI=10.1016/j.mib.2004.06.009;
RA   Delelis O., Lehmann-Che J., Saib A.;
RT   "Foamy viruses-a world apart.";
RL   Curr. Opin. Microbiol. 7:400-406(2004).
CC   -!- FUNCTION: The aspartyl protease activity mediates proteolytic
CC       cleavages of Gag and Pol polyproteins. The reverse transcriptase
CC       (RT) activity converts the viral RNA genome into dsDNA in the
CC       cytoplasm, shortly after virus entry into the cell (early reverse
CC       transcription) or after proviral DNA transcription (late reverse
CC       transcription). RT consists of a DNA polymerase activity that can
CC       copy either DNA or RNA templates, and a ribonuclease H (RNase H)
CC       activity that cleaves the RNA strand of RNA-DNA heteroduplexes in
CC       a partially processive 3' to 5' endonucleasic mode. Conversion of
CC       viral genomic RNA into dsDNA requires many steps. A tRNA-Lys1,2
CC       binds to the primer-binding site (PBS) situated at the 5'-end of
CC       the viral RNA. RT uses the 3' end of the tRNA primer to perform a
CC       short round of RNA-dependent minus-strand DNA synthesis. The
CC       reading proceeds through the U5 region and ends after the repeated
CC       (R) region which is present at both ends of viral RNA. The portion
CC       of the RNA-DNA heteroduplex is digested by the RNase H, resulting
CC       in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA
CC       hybridizes with the identical R region situated at the 3' end of
CC       viral RNA. This template exchange, known as minus-strand DNA
CC       strong stop transfer, can be either intra- or intermolecular. RT
CC       uses the 3' end of this newly synthesized short ssDNA to perform
CC       the RNA-dependent minus-strand DNA synthesis of the whole
CC       template. RNase H digests the RNA template except for a polypurine
CC       tract (PPT) situated at the 5'-end and near the center of the
CC       genome. It is not clear if both polymerase and RNase H activities
CC       are simultaneous. RNase H probably can proceed both in a
CC       polymerase-dependent (RNA cut into small fragments by the same RT
CC       performing DNA synthesis) and a polymerase-independent mode
CC       (cleavage of remaining RNA fragments by free RTs). Secondly, RT
CC       performs DNA-directed plus-strand DNA synthesis using the PPT that
CC       has not been removed by RNase H as primer. PPT and tRNA primers
CC       are then removed by RNase H. The 3' and 5' ssDNA PBS regions
CC       hybridize to form a circular dsDNA intermediate. Strand
CC       displacement synthesis by RT to the PBS and PPT ends produces a
CC       blunt ended, linear dsDNA copy of the viral genome that includes
CC       long terminal repeats (LTRs) at both ends (By similarity).
CC       {ECO:0000250}.
CC   -!- FUNCTION: Integrase catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry
CC       into a cell and reverse transcription of the RNA genome in dsDNA.
CC       The first step in the integration process is 3' processing. This
CC       step requires a complex comprising at least the viral genome,
CC       matrix protein, and integrase. This complex is called the pre-
CC       integration complex (PIC). The integrase protein removes 2
CC       nucleotides from the 3' end of the viral DNA right (U5) end,
CC       leaving the left (U3) intact. In the second step, the PIC enters
CC       cell nucleus. This process is mediated through the integrase and
CC       allows the virus to infect both dividing (nuclear membrane
CC       disassembled) and G1/S-arrested cells (active translocation), but
CC       with no viral gene expression in the latter. In the third step,
CC       termed strand transfer, the integrase protein joins the previously
CC       processed 3' ends to the 5' ends of strands of target cellular DNA
CC       at the site of integration. It is however not clear how
CC       integration then proceeds to resolve the asymmetrical cleavage of
CC       viral DNA (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Endonucleolytic cleavage to 5'-
CC       phosphomonoester. {ECO:0000255|PROSITE-ProRule:PRU00408}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1). {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at
CC       least 1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- SUBUNIT: The protease is a homodimer, whose active site consists
CC       of two apposed aspartic acid residues. {ECO:0000255|PROSITE-
CC       ProRule:PRU00863}.
CC   -!- SUBCELLULAR LOCATION: Integrase: Virion {ECO:0000305}. Host
CC       nucleus. Host cytoplasm {ECO:0000305}. Note=Nuclear at initial
CC       phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Protease/Reverse transcriptase/ribonuclease
CC       H: Host nucleus {ECO:0000250}. Host cytoplasm {ECO:0000305}.
CC       Note=Nuclear at initial phase, cytoplasmic at assembly.
CC       {ECO:0000305}.
CC   -!- DOMAIN: The reverse transcriptase/ribonuclease H (RT) is
CC       structured in five subdomains: finger, palm, thumb, connection and
CC       RNase H. Within the palm subdomain, the "primer grip" region is
CC       thought to be involved in the positioning of the primer terminus
CC       for accommodating the incoming nucleotide. The RNase H domain
CC       stabilizes the association of RT with primer-template (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: Integrase core domain contains the D-x(n)-D-x(35)-E motif,
CC       named for the phylogenetically conserved glutamic acid and
CC       aspartic acid residues and the invariant 35 amino acid spacing
CC       between the second and third acidic residues. Each acidic residue
CC       of the D,D(35)E motif is independently essential for the 3'-
CC       processing and strand transfer activities of purified integrase
CC       protein (By similarity). {ECO:0000250}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by viral protease yield
CC       mature proteins. The protease is not cleaved off from Pol. Since
CC       cleavage efficiency is not optimal for all sites, long and active
CC       p65Pro-RT, p87Pro-RT-RNaseH and even some Pr125Pol are detected in
CC       infected cells. {ECO:0000269|PubMed:9696869}.
CC   -!- MISCELLANEOUS: The reverse transcriptase is an error-prone enzyme
CC       that lacks a proof-reading function. High mutations rate is a
CC       direct consequence of this characteristic. RT also displays
CC       frequent template switching leading to high recombination rate.
CC       Recombination mostly occurs between homologous regions of the two
CC       copackaged RNA genomes. If these two RNA molecules derive from
CC       different viral strains, reverse transcription will give rise to
CC       highly recombinated proviral DNAs.
CC   -!- MISCELLANEOUS: Foamy viruses are distinct from other retroviruses
CC       in many respects. Their protease is active as an uncleaved Pro-Pol
CC       protein. Mature particles do not include the usual processed
CC       retroviral structural protein (MA, CA and NC), but instead contain
CC       two large Gag proteins. Their functional nucleic acid appears to
CC       be either RNA or dsDNA (up to 20% of extracellular particles),
CC       because they probably proceed either to an early (before
CC       integration) or late reverse transcription (after assembly). Foamy
CC       viruses have the ability to retrotranspose intracellularly with
CC       high efficiency. They bud predominantly into the endoplasmic
CC       reticulum (ER) and occasionally at the plasma membrane. Budding
CC       requires the presence of Env proteins. Most viral particles
CC       probably remain within the infected cell.
CC   -!- SIMILARITY: Contains 1 integrase catalytic domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00457}.
CC   -!- SIMILARITY: Contains 1 peptidase A9 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00863}.
CC   -!- SIMILARITY: Contains 1 reverse transcriptase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00405}.
CC   -!- SIMILARITY: Contains 1 RNase H domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00408}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA46122.1; Type=Frameshift; Positions=1075; Evidence={ECO:0000305};
CC       Sequence=AAA66556.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U21247; AAB48112.1; -; Genomic_RNA.
DR   EMBL; Y07723; CAA68997.1; -; Genomic_DNA.
DR   EMBL; Y07724; CAA68999.1; -; Genomic_DNA.
DR   EMBL; Y07725; CAA69003.1; -; Genomic_DNA.
DR   EMBL; M19427; AAA66556.1; ALT_INIT; Genomic_RNA.
DR   EMBL; M54978; AAA46122.1; ALT_FRAME; Genomic_RNA.
DR   PDB; 2LSN; NMR; -; A=591-751.
DR   PDB; 2X6N; X-ray; 2.06 A; A/B/C/D/E/F=861-1060.
DR   PDB; 2X6S; X-ray; 2.29 A; A/B/C/D/E/F=861-1060.
DR   PDB; 2X74; X-ray; 2.34 A; A/B/C/D/E/F=861-1060.
DR   PDB; 2X78; X-ray; 2.00 A; A/B/C=861-1060.
DR   PDB; 3DLR; X-ray; 2.20 A; A=859-1058.
DR   PDB; 3L2Q; X-ray; 3.25 A; A/B=752-1143.
DR   PDB; 3L2R; X-ray; 2.88 A; A/B=752-1143.
DR   PDB; 3L2U; X-ray; 3.15 A; A/B=752-1143.
DR   PDB; 3L2V; X-ray; 3.20 A; A/B=752-1143.
DR   PDB; 3L2W; X-ray; 3.20 A; A/B=752-1143.
DR   PDB; 3OS0; X-ray; 2.81 A; A/B=752-1143.
DR   PDB; 3OS1; X-ray; 2.97 A; A/B=752-1143.
DR   PDB; 3OS2; X-ray; 3.32 A; A/B=752-1143.
DR   PDB; 3OY9; X-ray; 2.95 A; A/B=752-1143.
DR   PDB; 3OYA; X-ray; 2.85 A; A/B=752-1143.
DR   PDB; 3OYB; X-ray; 2.54 A; A/B=752-1143.
DR   PDB; 3OYC; X-ray; 2.66 A; A/B=752-1143.
DR   PDB; 3OYD; X-ray; 2.54 A; A/B=752-1143.
DR   PDB; 3OYE; X-ray; 2.74 A; A/B=752-1143.
DR   PDB; 3OYF; X-ray; 2.51 A; A/B=752-1143.
DR   PDB; 3OYG; X-ray; 2.56 A; A/B=752-1143.
DR   PDB; 3OYH; X-ray; 2.74 A; A/B=752-1143.
DR   PDB; 3OYI; X-ray; 2.72 A; A/B=752-1143.
DR   PDB; 3OYJ; X-ray; 2.68 A; A/B=752-1143.
DR   PDB; 3OYK; X-ray; 2.72 A; A/B=752-1143.
DR   PDB; 3OYL; X-ray; 2.54 A; A/B=752-1143.
DR   PDB; 3OYM; X-ray; 2.02 A; A/B=752-1143.
DR   PDB; 3OYN; X-ray; 2.68 A; A/B=752-1143.
DR   PDB; 3S3M; X-ray; 2.49 A; A/B=752-1143.
DR   PDB; 3S3N; X-ray; 2.49 A; A/B=752-1143.
DR   PDB; 3S3O; X-ray; 2.55 A; A/B=752-1143.
DR   PDB; 4BAC; X-ray; 3.26 A; A/B=752-1143.
DR   PDB; 4BDY; X-ray; 2.52 A; A/B=752-1143.
DR   PDB; 4BDZ; X-ray; 2.85 A; A/B=752-1143.
DR   PDB; 4BE0; X-ray; 2.68 A; A/B=752-1143.
DR   PDB; 4BE1; X-ray; 2.71 A; A/B=752-1143.
DR   PDB; 4BE2; X-ray; 2.38 A; A/B=752-1143.
DR   PDB; 4E7H; X-ray; 2.57 A; A/B=752-1143.
DR   PDB; 4E7I; X-ray; 2.53 A; A/B=752-1143.
DR   PDB; 4E7J; X-ray; 3.15 A; A/B=752-1143.
DR   PDB; 4E7K; X-ray; 3.02 A; A/B=752-1143.
DR   PDB; 4E7L; X-ray; 3.00 A; A/B=752-1143.
DR   PDB; 4IKF; X-ray; 3.40 A; A/B=752-1143.
DR   PDBsum; 2LSN; -.
DR   PDBsum; 2X6N; -.
DR   PDBsum; 2X6S; -.
DR   PDBsum; 2X74; -.
DR   PDBsum; 2X78; -.
DR   PDBsum; 3DLR; -.
DR   PDBsum; 3L2Q; -.
DR   PDBsum; 3L2R; -.
DR   PDBsum; 3L2U; -.
DR   PDBsum; 3L2V; -.
DR   PDBsum; 3L2W; -.
DR   PDBsum; 3OS0; -.
DR   PDBsum; 3OS1; -.
DR   PDBsum; 3OS2; -.
DR   PDBsum; 3OY9; -.
DR   PDBsum; 3OYA; -.
DR   PDBsum; 3OYB; -.
DR   PDBsum; 3OYC; -.
DR   PDBsum; 3OYD; -.
DR   PDBsum; 3OYE; -.
DR   PDBsum; 3OYF; -.
DR   PDBsum; 3OYG; -.
DR   PDBsum; 3OYH; -.
DR   PDBsum; 3OYI; -.
DR   PDBsum; 3OYJ; -.
DR   PDBsum; 3OYK; -.
DR   PDBsum; 3OYL; -.
DR   PDBsum; 3OYM; -.
DR   PDBsum; 3OYN; -.
DR   PDBsum; 3S3M; -.
DR   PDBsum; 3S3N; -.
DR   PDBsum; 3S3O; -.
DR   PDBsum; 4BAC; -.
DR   PDBsum; 4BDY; -.
DR   PDBsum; 4BDZ; -.
DR   PDBsum; 4BE0; -.
DR   PDBsum; 4BE1; -.
DR   PDBsum; 4BE2; -.
DR   PDBsum; 4E7H; -.
DR   PDBsum; 4E7I; -.
DR   PDBsum; 4E7J; -.
DR   PDBsum; 4E7K; -.
DR   PDBsum; 4E7L; -.
DR   PDBsum; 4IKF; -.
DR   ProteinModelPortal; P14350; -.
DR   SMR; P14350; 8-98.
DR   DIP; DIP-58582N; -.
DR   MEROPS; A09.001; -.
DR   EvolutionaryTrace; P14350; -.
DR   PMAP-CutDB; O12817; -.
DR   Proteomes; UP000008228; Genome.
DR   GO; GO:0030430; C:host cell cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:UniProtKB-EC.
DR   GO; GO:0015074; P:DNA integration; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; IEA:UniProtKB-KW.
DR   GO; GO:0046718; P:viral entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.420.10; -; 2.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR001641; Spumavirus_A9.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF03539; Spuma_A9PTase; 1.
DR   PRINTS; PR00920; SPUMVIRPTASE.
DR   ProDom; PD013079; Peptidase_A9_cat; 1.
DR   SUPFAM; SSF53098; SSF53098; 2.
DR   PROSITE; PS51531; FV_PR; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS50879; RNASE_H; 1.
DR   PROSITE; PS50878; RT_POL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Aspartyl protease; Complete proteome; DNA integration;
KW   DNA recombination; DNA-directed DNA polymerase; Endonuclease;
KW   Host cytoplasm; Host nucleus; Hydrolase; Magnesium; Metal-binding;
KW   Multifunctional enzyme; Nuclease; Nucleotidyltransferase; Protease;
KW   RNA-binding; RNA-directed DNA polymerase; Transferase;
KW   Viral genome integration; Viral penetration into host nucleus; Virion;
KW   Virus entry into host cell.
FT   CHAIN         1   1143       Pro-Pol polyprotein.
FT                                /FTId=PRO_0000125483.
FT   CHAIN         1    751       Protease/Reverse
FT                                transcriptase/ribonuclease H.
FT                                /FTId=PRO_0000245443.
FT   CHAIN         1    596       Protease/Reverse transcriptase.
FT                                /FTId=PRO_0000245444.
FT   CHAIN       597    751       Ribonuclease H.
FT                                /FTId=PRO_0000245445.
FT   CHAIN       752   1143       Integrase.
FT                                /FTId=PRO_0000245446.
FT   DOMAIN        1    143       Peptidase A9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00863}.
FT   DOMAIN      198    363       Reverse transcriptase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00405}.
FT   DOMAIN      590    748       RNase H. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00408}.
FT   DOMAIN      868   1024       Integrase catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00457}.
FT   ACT_SITE     24     24       For protease activity.
FT                                {ECO:0000305|PubMed:7474150}.
FT   METAL       252    252       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       314    314       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       315    315       Magnesium; catalytic; for reverse
FT                                transcriptase activity. {ECO:0000250}.
FT   METAL       599    599       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000305}.
FT   METAL       646    646       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL       669    669       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL       740    740       Magnesium; catalytic; for RNase H
FT                                activity. {ECO:0000250}.
FT   METAL       874    874       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   METAL       936    936       Magnesium; catalytic; for integrase
FT                                activity. {ECO:0000250}.
FT   SITE        596    597       Cleavage; by viral protease; partial.
FT   SITE        751    752       Cleavage; by viral protease.
FT   MUTAGEN      24     24       D->A: Complete loss of Gag processing and
FT                                of Pol processing. Particles are non-
FT                                infectious. {ECO:0000269|PubMed:7474150}.
FT   MUTAGEN      25     25       S->T: No effect on polyprotein processing
FT                                and viral replication.
FT                                {ECO:0000269|PubMed:7474150}.
FT   MUTAGEN     152    152       P->G: No effect on RT or RNase H
FT                                activities. {ECO:0000269|PubMed:7544460}.
FT   MUTAGEN     169    169       P->G: 30% loss of RT activity.
FT                                {ECO:0000269|PubMed:7544460}.
FT   MUTAGEN     193    193       P->G: 40% loss of RT activity.
FT                                {ECO:0000269|PubMed:7544460}.
FT   MUTAGEN     599    599       D->A: 95% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:7544460}.
FT   MUTAGEN     672    672       Y->F: 50% loss of RNase H activity.
FT                                {ECO:0000269|PubMed:7544460}.
FT   STRAND      593    603       {ECO:0000244|PDB:2LSN}.
FT   STRAND      613    621       {ECO:0000244|PDB:2LSN}.
FT   STRAND      624    626       {ECO:0000244|PDB:2LSN}.
FT   STRAND      629    639       {ECO:0000244|PDB:2LSN}.
FT   HELIX       642    659       {ECO:0000244|PDB:2LSN}.
FT   STRAND      660    662       {ECO:0000244|PDB:2LSN}.
FT   STRAND      664    669       {ECO:0000244|PDB:2LSN}.
FT   HELIX       671    678       {ECO:0000244|PDB:2LSN}.
FT   HELIX       680    686       {ECO:0000244|PDB:2LSN}.
FT   STRAND      693    695       {ECO:0000244|PDB:2LSN}.
FT   HELIX       700    712       {ECO:0000244|PDB:2LSN}.
FT   STRAND      717    720       {ECO:0000244|PDB:2LSN}.
FT   STRAND      723    725       {ECO:0000244|PDB:2LSN}.
FT   STRAND      727    729       {ECO:0000244|PDB:2LSN}.
FT   HELIX       731    749       {ECO:0000244|PDB:2LSN}.
FT   HELIX       760    767       {ECO:0000244|PDB:3OYM}.
FT   STRAND      773    775       {ECO:0000244|PDB:3L2V}.
FT   STRAND      777    779       {ECO:0000244|PDB:3L2R}.
FT   STRAND      781    784       {ECO:0000244|PDB:3OYM}.
FT   STRAND      787    792       {ECO:0000244|PDB:3OYM}.
FT   STRAND      795    798       {ECO:0000244|PDB:3OYM}.
FT   HELIX       802    804       {ECO:0000244|PDB:3OYM}.
FT   HELIX       805    814       {ECO:0000244|PDB:3OYM}.
FT   TURN        815    817       {ECO:0000244|PDB:3OYM}.
FT   HELIX       820    828       {ECO:0000244|PDB:3OYM}.
FT   HELIX       836    844       {ECO:0000244|PDB:3OYM}.
FT   HELIX       848    853       {ECO:0000244|PDB:3OYM}.
FT   STRAND      858    860       {ECO:0000244|PDB:3OYM}.
FT   STRAND      874    881       {ECO:0000244|PDB:2X78}.
FT   STRAND      892    898       {ECO:0000244|PDB:2X78}.
FT   TURN        899    901       {ECO:0000244|PDB:2X78}.
FT   STRAND      904    912       {ECO:0000244|PDB:2X78}.
FT   HELIX       914    924       {ECO:0000244|PDB:2X78}.
FT   TURN        925    927       {ECO:0000244|PDB:2X78}.
FT   STRAND      931    935       {ECO:0000244|PDB:2X78}.
FT   HELIX       939    942       {ECO:0000244|PDB:2X78}.
FT   HELIX       944    953       {ECO:0000244|PDB:2X78}.
FT   STRAND      956    959       {ECO:0000244|PDB:2X78}.
FT   HELIX       965    968       {ECO:0000244|PDB:3OYM}.
FT   HELIX       970    987       {ECO:0000244|PDB:2X78}.
FT   TURN        990    996       {ECO:0000244|PDB:2X78}.
FT   HELIX       997   1005       {ECO:0000244|PDB:2X78}.
FT   TURN       1010   1012       {ECO:0000244|PDB:2X78}.
FT   HELIX      1016   1021       {ECO:0000244|PDB:2X78}.
FT   STRAND     1023   1025       {ECO:0000244|PDB:2X6N}.
FT   STRAND     1028   1030       {ECO:0000244|PDB:2X74}.
FT   TURN       1033   1036       {ECO:0000244|PDB:3OYM}.
FT   HELIX      1040   1054       {ECO:0000244|PDB:2X78}.
FT   STRAND     1073   1077       {ECO:0000244|PDB:3OYM}.
FT   STRAND     1092   1099       {ECO:0000244|PDB:3OYM}.
FT   STRAND     1102   1106       {ECO:0000244|PDB:3OYM}.
FT   STRAND     1108   1110       {ECO:0000244|PDB:4BE2}.
FT   STRAND     1112   1116       {ECO:0000244|PDB:3OYM}.
FT   HELIX      1117   1119       {ECO:0000244|PDB:3OYM}.
FT   STRAND     1120   1122       {ECO:0000244|PDB:3OYM}.
SQ   SEQUENCE   1143 AA;  129742 MW;  786E3203B06FFB3C CRC64;
     MNPLQLLQPL PAEIKGTKLL AHWDSGATIT CIPESFLEDE QPIKKTLIKT IHGEKQQNVY
     YVTFKVKGRK VEAEVIASPY EYILLSPTDV PWLTQQPLQL TILVPLQEYQ EKILSKTALP
     EDQKQQLKTL FVKYDNLWQH WENQVGHRKI RPHNIATGDY PPRPQKQYPI NPKAKPSIQI
     VIDDLLKQGV LTPQNSTMNT PVYPVPKPDG RWRMVLDYRE VNKTIPLTAA QNQHSAGILA
     TIVRQKYKTT LDLANGFWAH PITPESYWLT AFTWQGKQYC WTRLPQGFLN SPALFTADVV
     DLLKEIPNVQ VYVDDIYLSH DDPKEHVQQL EKVFQILLQA GYVVSLKKSE IGQKTVEFLG
     FNITKEGRGL TDTFKTKLLN ITPPKDLKQL QSILGLLNFA RNFIPNFAEL VQPLYNLIAS
     AKGKYIEWSE ENTKQLNMVI EALNTASNLE ERLPEQRLVI KVNTSPSAGY VRYYNETGKK
     PIMYLNYVFS KAELKFSMLE KLLTTMHKAL IKAMDLAMGQ EILVYSPIVS MTKIQKTPLP
     ERKALPIRWI TWMTYLEDPR IQFHYDKTLP ELKHIPDVYT SSQSPVKHPS QYEGVFYTDG
     SAIKSPDPTK SNNAGMGIVH ATYKPEYQVL NQWSIPLGNH TAQMAEIAAV EFACKKALKI
     PGPVLVITDS FYVAESANKE LPYWKSNGFV NNKKKPLKHI SKWKSIAECL SMKPDITIQH
     EKGISLQIPV FILKGNALAD KLATQGSYVV NCNTKKPNLD AELDQLLQGH YIKGYPKQYT
     YFLEDGKVKV SRPEGVKIIP PQSDRQKIVL QAHNLAHTGR EATLLKIANL YWWPNMRKDV
     VKQLGRCQQC LITNASNKAS GPILRPDRPQ KPFDKFFIDY IGPLPPSQGY LYVLVVVDGM
     TGFTWLYPTK APSTSATVKS LNVLTSIAIP KVIHSDQGAA FTSSTFAEWA KERGIHLEFS
     TPYHPQSGSK VERKNSDIKR LLTKLLVGRP TKWYDLLPVV QLALNNTYSP VLKYTPHQLL
     FGIDSNTPFA NQDTLDLTRE EELSLLQEIR TSLYHPSTPP ASSRSWSPVV GQLVQERVAR
     PASLRPRWHK PSTVLKVLNP RTVVILDHLG NNRTVSIDNL KPTSHQNGTT NDTATMDHLE
     KNE
//
